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Chlorhexidine-containing chewing gum. Clinical documentation
Abstract
A clinical documentation on chlorhexidine containing chewing gum is presented on the occasion of the
launch of CHewX, a chewing gum containing 5 mg of chlorhexidine diacetate in Switzerland. Following
an overview on functional chewing gum, the mechanism of action of chlorhexidine (CHX), its toxicity
and safety are summarized and a review of clinical studies performed with CHX-containing chewing
gum given. Indication, dosage, precautions and benefits of CHX chewing gum are described.
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A clinical documentation on chlorhexidine containing chew-
ing gum is presented on the occasion of the launch of 
CHewX®, a chewing gum containing 5 mg of chlorhexidine 
diacetate in Switzerland. Following an overview on functional 
chewing gum, the mechanism of action of chlorhexidine 
(CHX), its toxicity and safety are summarized and a review of 
clinical studies performed with CHX-containing chewing gum 
given. Indication, dosage, precautions and beneﬁ ts of CHX 
chewing gum are described.
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Introduction
Chewing gum with chlorhexidine
In spring 2006, CHewX®, a chewing gum containing 5 mg chlor-
hexidine diacetate per pellet, was introduced to the Swiss market
by the distributor ﬁ rm heicoDent. The following clinical docu-
mentation for the chlorhexidine containing chewing gum will 
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present the mechanism of action of chlorhexidine (CHX), its 
toxicity and safety along with a review of clinical studies per-
formed with CHX chewing gum. Indications, dosage, precautions 
and beneﬁ ts of this new galenic form of CHX, CHewX®, will be 
described.
Chlorhexidine
Dental plaque, a bacterial bioﬁ lm, is one of the major etiologic 
agents involved in the initiation and progression of dental caries, 
gingivitis and periodontal disease. The recognition of the role of 
microorganisms as the major cause of chronic gingivitis was early
established (ASH et al. 1964; LÖE et al. 1965; THEILADE et al. 1966). 
The association of particular organisms with caries and perio-
dontal disease has since been described. Owing to the strong 
association between oral microorganisms and caries as well as 
periodontal diseases, the dental profession has been increasingly
interested in the topical use of antimicrobial agents. Chemical
therapy has, however, primarily been used as an adjunct to me-
chanical therapy.
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CHX was the ﬁ rst antimicrobial agent shown to inhibit dental 
plaque formation and the development of chronic gingivitis (LÖE
& SCHIOTT 1970). CHX is not effective against systemic infections 
following parenteral dosing. Its use is restricted to prophylactic
antisepsis by topical or oral application.
CHX is a cationic chlorophenyl bisbiguanide antiseptic. Bisbigua-
nides are the primary second-generation antiplaque agents ex-
hibiting considerable substantivity and very broad antibacterial
properties. CHX is a strong base and, at physiologic pH, is a large 
dicationic molecule [1,6-di(4-chlorophenyl-diguanido) hexane] 
with two positive charges distributed over the nitrogen atoms on
either side of the hexamethylene bridge (JONES 1997; ALBERT & 
SARGEANT 1962). By virtue of its positive charge, CHX has the 
ability to bind to negatively charged surfaces such as the bacterial
cell wall (KOONTONGKAEW & JITPUKDEEBODINTRA 1995). Since 
most intraoral surfaces are negatively charged the drug gets well
distributed in the oral cavity and is not easily displaced (LOESCHE
1976). Once bound, it can exert its bacteriostatic and bactericidal
effects. The substantivity of CHX is given by the fact that once
adsorbed to intraoral surfaces it gets only slowly displaced by
calcium ions from saliva. The dicationic nature making CHX 
extremely interactive with anions is not only relevant to its efﬁ -
cacy, safety, but also to local side effects and difﬁ culties with 
product formulation.
CHX is available as digluconate, acetate or hydrochloride salt.
Digluconate and acetate salts are water soluble, CHX hydrochlo-
ride is weakly soluble in water. CHX, developed by Imperial 
Chemical Industries, GB, after intensive investigations of the 
biological properties of polybiguanide compounds, was ﬁ rst 
marketed as an antiseptic for skin wounds in 1953. It has under-
gone extensive laboratory testing.
Current applications of CHX in general medicine include: Skin 
disinfection, surgical hand disinfection, hygienic hand disinfec-
tion, preoperative whole-body disinfection, urology (irrigant, 
lubricant and antiseptic), obstetrics and gynecology (irrigant and
antiseptic), nasal cavity and throat, wounds and burns.
In dental medicine, CHX was initially used for presurgical disin-
fection of the mouth and in endodontology. Plaque inhibition by
CHX was already investigated in 1962 (SCHRÖDER 1969) but the 
ﬁ rst controlled clinical study was performed by LÖE & SCHIOTT
(1970). This study showed that rinsing for 60 sec, twice per day
with 10 ml of a 0.2% (20 mg dose) CHX gluconate solution, in 
the absence of normal toothcleaning inhibited plaque regrowth 
and the development of gingivitis. Numerous studies have fol-
lowed such that CHX is one of the best investigated compounds 
in dentistry and to date still remains the gold standard to which
other antiplaque and antigingivitis agents are compared. Reviews
have been published by GJERMO, 1989; ADDY et al. 1994 and 
MOSHREFI 2002. For purposes of dental medicine, CHX is mar-
keted and routinely used in various galenic forms such as 
mouthrinse, toothpaste, spray, gel, varnish and pastille or loz-
enge.
Functional chewing gum
1. Medicinal chewing gum
Although the ﬁ rst medicated chewing gum, Aspergum®, was 
introduced in the USA as early as 1924, the great potential of 
chewing gum as a galenic form for drug delivery has gone fairly
unnoticed to date. Chewing gum is, however, listed as a dosage 
form in pharmaceutical guidelines and as a standard in the 
 European Pharmacopoeia (COMMISSION OF THE EUROPEAN COM-
MUNITIES 1991; EUROPEAN DEPARTMENT FOR THE QUALITY OF MED-
ICINE 2001). The advantages of chewing gum as a carrier for drugs 
are obvious: Chewing gum can be used without water, at any 
time, and everywhere. Product stability is good, because incor-
porated therapeutic agents are protected from oxygen, light and
water. Chewing gum as a drug delivery system has been reviewed 
by RASSING (1994; 1996) and a representative list of medicinal 
chewing gums sold worldwide was published by IMFELD (1999).
2. Dental chewing gum
Chewing gum as a delivery system for various topical dental 
prophylactic and therapeutic agents has been repeatedly studied,
and a few dental chewing gum products are registered and mar-
keted in various countries (IMFELD 1999). Thus, there are gums 
containing ﬂ uoride, enzymes, mineral salts, metal salts, xylitol, 
carbamide and CHX diacetate.
Mechanism of action of CHX
CHX has a broad spectrum of antimicrobial activity including a 
wide range of Gram-positive and Gram-negative bacteria (WADE
& ADDY 1989), yeasts, dermatophytes and some lipophylic viruses 
including HBV and HIV (DENTON 1991).
The antibacterial action of CHX shows different effects at differ-
ent concentrations. At low concentrations, the agent is rapidly
bacteriostatic, and at higher concentrations, it is bactericidal
(JONES 1997). CHX’s antimicrobial activity is based on its mem-
brane binding activity. As the CHX molecule is positively charged, 
it binds strongly to the negatively charged bacterial cell mem-
branes. The binding is speciﬁ c and strongly adsorptive to phos-
phate-containing compounds. At low concentration, the binding 
results in a disorientation of the lipoprotein structure of the cell 
membrane thus inducing an increased membrane permeability 
and leakage of intracellular components including potassium 
(HUGO & LONGWORTH 1964, 1965). At higher concentration, the 
molecule binds to phospholipids in the inner membrane, leading 
to increased permeability of the latter and leakage of low-mo-
lecular-weight molecules. This causes precipitation of bacterial
cytoplasm and cell death (HUGO & LONGWORTH 1966). Cells 
treated with bacteriostatic levels of CHX can recover viability
despite having lost up to 50% of their potassium storage (DENTON
1991). As the concentration of the compound increases, higher 
molecular weight cellular constituents, such as nucleotides, ap-
pear in the supernatant ﬂ uid surrounding the bacterial cell. 
Levels of CHX producing this effect are bactericidal (DENTON
1991).
In the mouth, CHX readily adsorbs to negatively charged sur-
faces, including the mucosa and pellicle-coated teeth. Unlike 
most other antiseptics, once adsorbed, CHX still remains bacte-
riostatically active. A single rinse with 0.2% (Europe) or 0.12%
(USA) CHX will maintain substantivity at antibacterial levels 
within the saliva for up to ﬁ ve hours (ROBERTS & ADDY 1981; 
Schiott 1973). Persistence at the oral surfaces has been shown to
suppress salivary bacterial counts for over 12 hours (SCHIOTT
1973).
Studies with radiolabelled CHX suggested a slow release of the 
antiseptic from surfaces (BONESVOLL et al. 1974). Approximately 
30% of the dose, i.e. 5.5 to 6.0 mg CHX, is retained after a 60-sec
mouth rinse with 10 ml of a 0.2% solution (BONESVOLL 1977). It 
was hypothesised that this leads to a persistent antibacterial 
milieu in the mouth (GJERMO et al. 1974). JENKINS et al. (1989) 
suggested that the plaque inhibitory action of CHX is derived 
only from the CHX adsorbed to the tooth surface. It is possible
that the molecule attaches to pellicle on the tooth surface by one
cation, leaving the other cation free to interact with bacteria at-
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tempting to colonize. The same mechanism is most probably 
associated with toothstaining. This would explain why anionic 
substances such as sodium lauryl sulfate, contained in most 
toothpastes, reduce the plaque inhibition of CHX if the latter are 
used shortly after rinses with the antiseptic (BARKVOLL et al. 
1989). Short-term use of CHX causes a striking reduction in the
number of oral microorganisms. In the absence of other oral 
hygiene measures, CHX has been shown to reduce the number 
of bacteria in saliva by 85% after only 24 hours. A maximum 
reduction of 95% occurred after around ﬁ ve days. After this the 
numbers of bacteria gradually increased, but an overall reduction
of 70–80% was maintained at 40 days. Cessation of CHX mouth 
rinses results in a return of normal salivary bacterial counts.
Plaque inhibition by CHX mouthrinses appears to be dose re-
lated (CANCRO et al. 1974; JENKINS et al. 1994; AGERBAEK et al. 
1975). The best results have been obtained when using two daily
rinses with an aqueous solution of CHX gluconate (GJERMO et al. 
1970; LÖE & SCHIOTT 1970; CANCRO et al. 1972; MADSEN 1974). 
Similar effects as seen with 10 ml rinses of 0.2% solutions (20 mg 
CHX) can also be achieved with high volumes of low concentra-
tion solutions (CUMMING & LÖE 1973; AGERBAEK et al. 1975; LANG
& RAMSEIER-GROSSMAN 1981). It is, however, noteworthy that a 
considerable plaque inhibition is obtained with doses as low as
1–2 mg twice daily (JENKINS et al. 1994). Topical applications of 
0.2% solutions of CHX to the tooth surface only (spray), pro-
duced the same level of plaque inhibition as rinsing with the full
dose of 20 mg CHX (ADDY & MORAN 1983; JENKINS et al. 1989; 
KALAGA et al. 1989a, b).
Toxicity and safety of CHX
Absorption
The cationic nature of CHX minimizes absorption through skin 
and mucosae including that of the gastrointestinal tract. Studies
with radiolabelled CHX showed that when CHX is swallowed, 
the drug binds to the mucosal surfaces of the alimentary tract.
The expired cells are desquamated and together with any on-
bound CHX are excreted in the feces. Thus, practically all CHX 
swallowed is excreted in the feces (WINROW 1973). The very small 
amount of CHX that may be absorbed is minimally metabolized 
in the liver and excreted in urine (WINROW 1973). No systemic 
toxicity even from long-term topical application and ingestion 
has been reported (GJERMO 1989). Intravenous infusion in ani-
mals is well tolerated and has even accidentally occurred in 
humans without serious consequences (FOULKES 1973; DENTON
1991). When orally ingested, LD50 for CHX is 2,000 mg/kg body 
weight. This means that individuals with an average body weight
of 70 kg would need to drink 70 liters of a 0.2% CHX solution at
once in order to kill 50% of the test population. (As many CHX 
rinses contain alcohol, they would die from the ethyl alcohol 
content of such rinses long before reaching 70 liters!).
Teratogenic effects: Pregnancy category B
Reproduction studies have been performed in rats and rabbits at
CHX gluconate doses up to 300 mg/kg/day and 40 mg/kg/day, 
respectively, and have not revealed evidence of harm to the fetus
(FOULKES 1973). Adequate and well-controlled studies in preg-
nant women have, however, not been attempted.
Carcinogenesis, mutagenesis, and impairment of fertility
In a drinking water study in rats, carcinogenic effects were not
observed at doses up to 38 mg/kg/day. Mutagenic effects were 
not observed in two mammalian in vivo mutagenesis studies 
with CHX gluconate. The highest doses of CHX used in a mouse 
dominant-lethal assay and a hamster cytogenetics test were 
1,000 mg/kg/day and 250 mg/kg/day, respectively. No evidence 
of impaired fertility was observed in rats at doses up to 100 mg/
kg/day (FOULKES 1973).
Neurosensory deafness
This can occur if CHX is introduced into the middle ear. The 
antiseptic should not be placed in the outer ear in case the ear
drum is perforated.
Nursing mothers
It is not known whether CHX is excreted in human milk. Because 
many drugs are excreted in human milk, caution might be indi-
cated when CHX is administered to a nursing woman. In partu-
rition and lactation studies with rats, no evidence of impaired
parturition or of toxic effects to suckling pups was observed when
CHX gluconate was administered to dams at doses that were 
over three g per day.
Bacterial resistance
Resistance has not been reported even in long-term oral use. 
There is no evidence of superinfection by fungi, yeasts or viruses. 
Long-term oral use resulted in a small shift in the ﬂ ora towards 
less sensitive organisms but the effect was rapidly reversible after
discontinuation of use (SCHIOTT et al. 1976).
Oral side effects of CHX
Staining
When used as a mouthrinse, CHX has a number of local oral side 
effects (LÖE & SCHIOTT 1970; FLOTRA et al. 1971). The most com-
mon is a brown discoloration of the teeth, some restorative 
materials, the mucosae and notably the dorsum of the tongue. 
Cosmetic problems associated with intraoral staining are a factor
decreasing patient compliance. The amount of staining seems to 
be dependent on the mode of application, concentration, and 
presence of potential discoloring agents within the diet. The 
mechanisms at the origin of the CHX-staining are still debated 
(ERIKSEN et al. 1985, ADDY & MORAN 1995). The following expla-
nations have been proposed:
–  degradation of the CHX molecule to release parachloraniline,
–  catalysis of Maillard reactions,
–  protein denaturation with metal sulﬁ de formation,
–  precipitation of anionic dietary chromogens.
Release of parachloraniline, however, does not occur on storage
or as a result of metabolic processes and Alexidine, a similar 
bisbiguanide, not having any parachloraniline groups, also causes
staining identical to that of CHX (ROBERTS & ADDY 1981). Non-
enzymatic browning reactions (Maillard reactions) catalyzed by 
CHX are theoretically possible (NORDBØ 1979), however, evidence 
is indirect, circumstantial or inconclusive (ERIKSEN et al. 1985). 
The same holds true for protein denaturation produced by CHX. 
Staining due to precipitation of anionic dietary chromogens by 
cationic antiseptics, including CHX and polyvalent metal ions, 
is supported by a number of controlled laboratory and clinical 
studies (for review see ADDY & MORAN 1995). Thus, the locally 
bound antiseptics or metal ions on the mucosa or on the teeth 
can react with polyphenols in dietary substances to produce 
staining. Beverages such as tea, coffee and red wine are par-
ticularly chromogenic. The stain is of extrinsic origin and easily 
removable from the tooth surfaces by professional oral hygiene 
measures.
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weight was found when CHX-containing gums were used 
(AINAMO & ETEMADZADEH 1987).
A ﬁ ve-day crossover, investigator-blind clinical study was per-
formed with six adult volunteers to compare the antiplaque ef-
fects of (i) daily chewing of 22 pieces of CHX gum (5 mg CHX 
per gum, total daily CHX = 20 mg), (ii) two daily rinses with 
10 ml of Hibitane® mouthwash (0.2% CHX gluconate, total daily 
CHX = 40 mg), and (iii) chewing gum base with neither CHX nor 
any sweetening agent in the absence of oral hygiene. The CHX-
containing chewing gums inhibited plaque growth (plaque index 
and area %) as effectively as did the Hibitane® rinses (AINAMO et 
al. 1990).
The same study design was used with eight adult volunteers for 
six days and using CHX-containing gums with 5, 4 and 3 mg of 
CHX acetate (total daily CHX = 20 mg, 16 mg and 12 mg). Also 
the lower doses inhibited plaque growth as well as the CHX 
rinses (AINAMO et al. 1990).
A six-day, double-blind, three-treatment, crossover clinical trial
with 14 adult volunteers was made to compare dental plaque 
formation without mechanical oral hygiene when chewing ﬁ ve 
pieces per day of (i) CHX-containing gum (5 mg CHX acetate 
per gum, total daily CHX = 25 mg), (ii) xylitol gum (0.8 g xylitol
per gum) and (iii) sorbitol gum (1.0 g sorbitol per gum). The gums
were chewed for 20 min on each occasion. Chewing CHX-con-
taining gum resulted in signiﬁ cantly reduced plaque values 
compared to the sorbitol- and xylitol-containing gums (TELLEFSEN
et al. 1996).
The clinical effectiveness in controlling supragingival plaque and
the stain-forming potential of CHX-containing gum was inves-
tigated in an eight-week, randomized, single-center, investiga-
tor-blind, parallel designed clinical trial employing three groups
of 50 adult volunteers each (total n = 150). Group 1 chewed 22
pieces of CHX-containing gum for 10 min (5 mg CHX per gum, 
total daily CHX = 20 mg). Group 2 likewise chewed placebo gum 
and Group 3 rinsed twice daily with 10 ml of a 0.2% CHX aque-
ous solution for 1 min (total daily CHX = 40 mg). Plaque index,
gingival index, gingival bleeding index and indices of stain in-
tensity and stain extent were recorded at baseline, after four and
after eight weeks. After eight weeks of use, plaque and bleeding
scores in the CHX-chewing gum group were equal to those of 
the CHX-rinse group and signiﬁ cantly lower than those of the 
placebo group. Further, the staining intensity was signiﬁ cantly 
lower after eight weeks use of CHX-containing chewing gum 
than after eight weeks use of CHX-containing rinsing solution 
(SMITH et al. 1996). The authors concluded that the CHX-contain-
ing gum used twice daily provided signiﬁ cant beneﬁ ts to oral 
hygiene and gingival health.
The important ﬁ nding of less CHX-staining in conjunction with 
chewing gum was somewhat corroborated in a six-week clinical 
trial that showed that the use of sugar-free chewing gum after 
rinsing with CHX did not diminish the therapeutic effect of 
the CHX, but controlled some of the staining effect (YANKELL & 
EMLING 1997).
In order to assess the efﬁ cacy of CHX-containing gum as an oral 
delivery system for antibacterial agents in elderly patients with
salivary hypofunction and to monitor its acceptability among this
population, a clinical trial was performed with 53 volunteers aged
between 65 and 98 years (mean age 79.5 years) who had a 
minimum of six teeth and wore dentures. The study was a four-
week, randomized, single-center, double-blind, parallel designed
clinical trial with a test- (n = 26) and a placebo group (n = 27). 
While maintaining their normal mechanical oral hygiene, the 
test-group chewed two pieces of CHX-/xylitol-containing gum 
Bitter taste/taste disturbance
Aqueous solutions of CHX have a very bitter taste which is dif-
ﬁ cult to mask in dental products. Objective testing of the taste
sensation has also conﬁ rmed a transient effect on the perception 
of sweet and salt taste (GJERMO et al. 1974) with salt taste being 
preferencially affected (LANG et al. 1988). Similar impairments of 
taste perception occur with most strong cationic substances other
than CHX (GJERMO et al. 1970, 1974).
Mucosal desquamation
Desquamation and soreness of the oral mucosa in connection 
with mouth rinses with bisbiguanides have been sporadically 
reported (GJERMO et al. 1970) and have been explained by pre-
cipitation of the mucin layer weakening its lubricating effect 
(GJERMO et al. 1974). This side effect is concentration dependent 
and usually can be controlled by double diluting rinses. To main-
tain the dose and thereby the effect, a double volume has to be
rinsed.
In vitro studies with CHX showed that the total protein synthe-
sis is reduced, cell division is suppressed, and wound contraction
is affected (PUCHER & DANIEL 1992). The cytotoxicity observed in 
vitro is, however, not seen in vivo (SANCHEZ et al. 1988). Using 
an infected wound model, it was found that CHX accelerated the 
rate of healing compared with saline-treated models (DENTON
1991). This effect might be ascribed to decreased microbial irrita-
tion eventually also masking some cytotoxicity.
Clinical studies with CHX-containing 
chewing gum
The use of CHX as an adjunct to or even as a short-term replace-
ment for mechanical oral hygiene measures is well established. 
It is proven effective for treating gingivitis (STIEFEL et al. 1995, 
PERNU et al. 1996; VALENTE et al. 1996; BRETZ et al. 2000). Tradi-
tional methods of application of CHX, such as rinses or gels have, 
however, not proved acceptable in many special care patients 
(FRANCIS et al. 1987; CLARK et al. 1991; BURTNER et al. 1996). 
Moreover, the above mentioned disadvantages – bitter taste, 
impairment of taste perception, reversible staining of teeth and
tongue, and interaction with surface-active substances such as 
sodium lauryl sulfate, contained in most commercial toothpastes
– led to a search for alternatives to the traditional galenic forms. 
Thus CHX-containing chewing gum has been explored for the 
treatment of gingivitis, periodontitis and infections in the oral
cavity or throat.
The in vivo release of CHX acetate from chewing gum was 35% 
after 5 min and approximately 68% after 15 min of chewing 
(AINAMO & ETEMADZADEH 1987). This ﬁ nding promised a longer 
oral presence of CHX from chewing gum than after rinsing with 
a CHX mouthwash.
Several well controlled clinical studies in humans have since 
been performed with CHX-containing chewing gum. They are 
described in chronological order in the following.
The effect on plaque growth of a CHX-containing gum and of a 
placebo gum was assessed in a four-day double-blind, crossover 
clinical trial with 12 adult volunteers. During the trial no oral
hygiene measures were allowed except for the chewing of two 
pieces of test gum at a time for 10 min ﬁ ve times daily. CHX gums 
contained 5 mg CHX acetate each (total daily CHX = 50 mg). At 
the beginning and at the end of the test period plaque was as-
sessed using plaque index, plaque wet weight and area of plaque
on the tooth surface. No increase in plaque index and plaque wet
S c h w e i z  M o n a t s s c h r  Z a h n m e d ,  V o l  1 1 6 :  5 / 2 0 0 6480
F o r s c h u n g ·  W i s s e n s c h a f t
twice a day for 10 min (5 mg CHX per gum, total daily CHX =
20 mg). The placebo group chewed equal amounts of a xylitol-/ 
sorbitol-containing gum. Saliva samples were inoculated on 
selective media and colony forming units per ml saliva for 
S.mutans, yeasts and Lactobacilli were counted at baseline and 
after four weeks of gum use. Area and severity of stain as well as 
saliva ﬂ ow rates were assessed. The attitudes of the subjects to 
gum chewing were evaluated by questionnaires. The CHX-/xy-
litol-gum signiﬁ cantly reduced the salivary levels of S. mutans,
Lactobacilli and yeasts while the xylitol-placebo gum produced 
signiﬁ cant reductions in S. mutans only. The study population 
found chewing gum an acceptable method of receiving medica-
tion and improving oral health. The desire to continue gum use 
was signiﬁ cantly related to subjects’evaluation of oral dryness at 
baseline. Only those participants who had stained enamel at 
baseline exhibited increased enamel staining following CHX-/
xylitol-gum use (SIMONS et al. 1997).
The effect of CHX-containing gum on plaque accumulation and 
gingival inﬂ ammation in the absence of all oral hygiene measures 
was assessed in a ﬁ ve-day, randomized, single-center, double-
blind, crossover study with intermittent nine-day washout peri-
ods. Eight subjects with a mean age of 51.3 years participated.
After a professional tooth cleaning they used in a random order
(i) 22 pieces of a liquorice ﬂ avored CHX-/xylitol-containing 
chewing gum (5 mg CHX per gum, total daily CHX = 20 mg), (ii) 
22 pieces of a chocolate mint ﬂ avored CHX-/xylitol-containing 
gum (5 mg CHX per gum, total daily CHX = 20 mg), (iii) 21
pieces of a liquorice ﬂ avored CHX-/xylitol-containing gum (5 mg 
CHX per gum, total daily CHX = 10 mg) and (iv) 22 pieces of a 
liquorice ﬂ avored xylitol-containing gum without CHX. The gum 
was chewed for 15 min at a time. Plaque index, gingival index 
and intensity and area of stain were recorded at baseline and 
after the ﬁ ve-day study period. Plaque indices when chewing 
22 CHX-/xylitol gums (irrespective of ﬂ avor) were signiﬁ cantly 
lower than when chewing xylitol-containing gum. The gingival 
index was signiﬁ cantly higher after xylitol-containing gum than 
after the other chewing regimes. Stain indices demonstrated no 
differences for any of the gums chewed. The authors concluded 
that CHX-containing gum is useful to control dental plaque 
formation and to decrease gingival inﬂ ammation in the absence 
of mechanical hygiene routines (SIMONS et al. 1999a).
Oral health care, especially the prevention of stomatological 
problems, caries and periodontitis, is hampered among elderly 
occupants of residential homes. The main reasons are cost, low 
levels of perceived need by residents and staff, restricted mobil-
ity, diminished manual dexterity, impaired vision, physical limita-
tions such as stroke and arthritis and the carers’ lack of dental 
knowledge. Elderly occupants of residential homes are often 
dependent on their carers to perform all their daily care including
the maintenance of good oral hygiene. This may place consider-
able burdens on the staff, and unfortunately residents rarely 
receive more than emergency treatment for dental pain and 
discomfort.
In order to investigate the attitudes of elderly residents to using
an antimicrobial chewing gum as an aid to oral health, and to 
assess the opinion of their carers on such a procedure, a cross-
sectional, multi-center survey using a structured interview/ques-
tionnaire was conducted with elderly residents and their carers
in nine residential/nursing homes randomly chosen from the 
homes in West Hertfordshire, GB. 207 residents, aged between 
53–100 years (mean age 82.2 years) were asked to chew two 
pieces of CHX-containing gum twice daily for seven days (5 mg 
CHX per gum, total daily CHX = 20 mg). 47 carers were involved 
in distributing and collecting the gum. 59% of the residents were 
edentulous and 41% were partially dentate. 35% of the residents
found that chewing the gums was difﬁ cult with 18% of this group 
being unable to chew. 19% of the subjects disliked the ﬂ avor of 
the gum. Of the 170 persons who chewed the gum 57% found 
it reduced oral dryness and 45% reported it made their mouth 
feel healthy. 54% of the dentate and 41% of the edentate resi-
dents wished to keep using the gum. 75% of the carers found it 
easy to distribute the gum and 62% thought that chewing gum 
was an acceptable method of maintaining oral health for resi-
dents. The authors concluded that the antimicrobial gum was 
acceptable to many elderly occupants and their carers, and that
it signiﬁ cantly improved the perceived oral health and oral dry-
ness of residents (SIMONS et al. 1999b).
The long-term effect of CHX-containing chewing gum on plaque 
accumulation and gingival inﬂ ammation of elderly occupants in 
residential homes was assessed in a one-year, randomized, 
multi-center, double-blind, controlled clinical trial. 164 volun-
teers from 21 residential homes were involved. They were ran-
domly assigned to three groups. Group 1 chewed 22 pieces of 
a CHX-/xylitol-containing gum (5 mg CHX per gum, total daily 
CHX = 20 mg). Group 2 likewise chewed 22 pieces of xylitol-
containing gum (placebo) and Group 3 chewed no gum at all. 
Plaque and gingival indices were recorded at baseline, three, six, 
nine and 12 months. In the CHX-gum group, the plaque and 
gingival indices signiﬁ cantly decreased over the 12 months. In 
the xylitol-gum group, only the plaque score signiﬁ cantly de-
creased, and in the “no-gum” control group, both indices re-
mained high. The acceptance of both chewing gums was high 
but more participants in the CHX-gum group felt that the gum 
kept their mouth healthy. The effect of the CHX-gum on plaque 
and gingival indices was signiﬁ cantly greater than for the xylitol 
gum. The authors concluded that the long-term use of a CHX 
acetate-/xylitol-containing chewing gum supported oral hygiene 
routines in this elderly dependent population (SIMONS et al. 
2001).
The long-term effect of CHX-containing chewing gum on sali-
vary ﬂ ow rate, denture debris score, prevalence of angular cheili-
tis, denture stomatitis and salivary levels of caries associated
microorganisms was assessed in elderly residents of residential
homes in a one-year, randomized, multi-center, double-blind, 
controlled clinical trial. 111 volunteers from 16 residental homes
were involved. They were randomly assigned to three groups. 
Group 1 chewed 22 pieces of a CHX-/xylitol-containing gum 
(5 mg CHX per gum, total daily CHX = 20 mg). Group 2 likewise 
chewed 22 pieces of xylitol-containing gum (placebo) and 
Group 3 chewed no gum at all. Parafﬁ n stimulated whole saliva 
ﬂ ow (ml/min), colony forming units per ml of saliva of S. mutans,
yeasts and Lactobacilli (plate counting) and clinical examination
were performed at baseline, three, six, nine and 12 months. The
stimulated whole saliva ﬂ ow rate increased signiﬁ cantly for the 
CHX-gum and the xylitol-gum groups over baseline and over 
the“no-gum” group levels. The levels of S. mutans, Lactobacilli 
and yeasts signiﬁ cantly increased in the xylitol-gum and the 
“no-gum” groups. Denture debris status was signiﬁ cantly lower 
in the CHX-gum and the xylitol-gum groups than at baseline or 
in the “no-gum” group. The reductions of 91% and 75% in den-
ture stomatitis and angular cheilitis prevalence, respectively, that 
occurred in the CHX-gum group were signiﬁ cantly greater than 
the respective reductions in the xylitol-gum group. Prevalence of 
denture stomatitis and angular cheilitis were not signiﬁ cantly 
changed in the “no-gum” group. The authors concluded that the 
use of the medicated chewing gum signiﬁ cantly improved oral 
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Beneﬁ t – risk
CHX-containing chewing gum can be used as an antiplaque and 
antigingivitis agent.
It is a valid adjunct to individual oral hygiene in persons with
high caries activity, especially in oligosialic and xerostomic pa-
tients, in patients having undergone periodontal therapy and also
in persons temporarily or permanently unable to perform oral 
hygiene. CHX-gum is effective against bad breath.
The main risk is the appearance of light brown discolorations of
teeth, some restorative materials and the tongue. Staining is, 
however, easily removed by professional oral hygiene measures.
Zusammenfassung
Auf Grund der Markteinführung von CHewX®, einem Mund-
pﬂ egekaugummi mit 5 mg Chlorhexidin, in der Schweiz wird 
eine klinische Dokumentation von Chlorhexidin-Kaugummi 
präsentiert. Nach einer Übersicht über funktionelle Kaugummis 
wird der Wirkungsmechanismus von Chlorhexidin (CHX), die 
Toxizität und Sicherheit besprochen und eine Literaturübersicht
von klinischen Studien mit CHX-Kaugummi gegeben. Indikati-
onen, Kontraindikationen, Dosierung, Anwendungseinschrän-
kungen, unerwünschte Nebenwirkungen und die Vorteile der 
neuen Verabreichungsform von CHX werden besprochen.
Résumé
Après le lancement sur le marché suisse de CHewX®, un chewing 
gum contenant 5 mg de chlorexidine, une documentation cli-
nique des chewing gum contentant de la chlorexidine est pré-
sentée. Après un survol des différents chewing gum «fonction-
nels» existants, le mécanisme d’action de la chlorexidine, sa 
toxicité et sa sécurité d’emploi sont discutées et une revue d’étu-
des cliniques concernant les chewing gum à base de chlorexidine 
est présentée.
Les indications, contre-indications, dosages, effets secondaires, 
limitations d’emploi et avantages sont décrits.
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